Questions related to Cardiac Imaging
As Feigenbaum said, it takes only five minutes to perform a 2D longitudinal strain evaluation in patients who underwent cardiotoxic chemotherapy. Is it part of your routine cardiac ultrasound examination?
Appropriateness in medicine, specially in cardiovascular imaging is a wide concept, sometimes difficult to define. Most doctors think they are choosing tests appropriately. I would like to know what "appropriateness" is for you? (Please, forget for a while the concept of "appropriateness" in the Appropriate Use Criteria and the Rand-Ucla Method, if you can).
Is it obvious that VR can help medical education? Yes.
Then why are so many academic institutions resistant to implement this technology?
I would like to personally extend an offer to demonstrate hands on to any medical school interested and give a live demo opportunity to anyone in this sphere to learn about this technology.
I will travel anywhere in the world to promote this know how. It’s a rising tides float all boats equation. The VR community is in its diapers stage.
I want to use a MRI images dataset in order to detect heart failure with image processing techniques. In the beginning I should choose the kind of map I need. T1 map or T2 map, I should choose one of them.
But I don’t know what is the differences between them and which one is better for detecting heart failure.
Can anyone share some information about that?
I am interested to segment it (somehow) and get the motion information from an echo of the heart. Any comment also on this part?
For example, can we use information on pulse sequences available in articles to perform T1 mapping and how easy is it to implement?
For Cardiac Innervation Imaging 123-mIBG is used. Due to its non-availability, can I-131-mIBG with proper Thyroid block be used.
-It may be cost effective for the patient.
-Has got a long half life ?
Kindly provide references, if any.
With the increasing use of echocardiographic contrast for both endocardial border delineation , and in the evaluation of myocardial perfusion , we are faced with the indication for the procedure in pregnant women. Logically the contraindication due to the use of medication in the first quarter is present , but from there in situations where the examination is absolutely necessary. What to do? How far is safe use of echocardiographic contrast ?
I'm currently researching on left ventricle motion quantification. Can anyone suggest me any heart or left ventricle localization method in tagged cardiac MRI images? Appreciate if you can provide me references too. Thanks.
My group is trying to develop digital phantoms that will ultimately be useful when quantitatively characterizing scar tissue after cardiac ablation. I have found several papers on scar tissue in the cornea following refractive eye surgery et al, but nothing for cardiac tissue.
Alternatively, does anyone know the general composition of cardiac scar tissue (e.g., proportion of different types of collagen, muscle, etc.)? Many thanks in advance!
As far as I know, within several min after injection activity absorption would be in the highest value possible. What is "the" value in (Mbq/ml or mCi/ml) ?
Recent studies have shown to be feasible the use of thrombolysis by ultrasound. This is really a new therapeutic window? What we need to move forward to achieve this purpose?
In some papers they say dynamic SPECT provides a better contrast between normal and decreased ﬂow regions than can be obtained from static imaging. what are the other advantages,if any?
K1 and k2 are cardiac kinetic parameters which define wash-in and wash-out rate in a compartmental model of the cardiac muscle. j1 and j2 are two coefficients which are related to K1 and k2. using equation Count=-C1.exp(-j1.t)+C2.exp(-j2.t) time-acitivity curve for myocardium can be plotted which shows washin and washout rate of myocardium, but as far as I know K1 and k2 are somehow different from j1 and j2.
I would like to know about the strategies that are being developed to evaluate the role of peri-coronary fat in the development of coronary artery disease, mainly on the use of cardiac imaging and biochemical markers.
My department has recently purchased the Philips EPIQ which is the latest echo machine from them. I am now proactively using Speckle Tracking (mainly Radial and Longitudinal). However, I did not find any document (even by PHILIPS) which gives a clear idea of standardised parameters for global strain (age/sex/BMI adjusted). If anyone has come across this, I would really appreciate their input and suggestions.
I am interested in starting a collaboration on processing cardiac DW-MRI sequences. Our research group has experience in brain DW-MRI processing.
I am being protected stenting about 8 years in Symptomatic Carotid Disease. Because there is continuing debate inthis topic and I want to know the common idea in RG scientists.
ECHO is not raccomended in the guidelines for CRT selection, but in many centers still has a role especially in borderline situations
I need to measure length and size of heart cell branching. Normal HE histology sections cannot be used (too many artifacts and not possible to measure length with enough accuracy).
Is there any (2D or 3D) images that shows length and/or size of the branchings in a measurable way?
Many young patients are referred to cardiac MRI because of reduced exercise performance after infection. In these cases, we detect often an early enhancement, a small pericardial effusion and a small late enhancement. Left ventricular function is usually in the lower normal range.
According to the ADA´s guidelines from 1998, asymptomatic diabetic patients with risk factors should be subjected to a test to detect cardiac ischemia. However, these recommendations were not based on scientific evidence. What is your opinion on what should be done to these patients?
Current ACC/AHA/ESC guidelines do recommend implantation of an ICD in patients with hypertrophic cardiomyopathy (HCM) with 1 or more of the clasical risk factors for SCD (wall thickness greater than 30 mm, syncope, abnormal blood pressure during exercise test, asymptomatic non-sustained ventricular tachycardia and family history of sudden cardiac death-SCD-). Other factors such as age, diastolic dysfunction, left ventricular outflow tract gradient, and myocardial ischemia (myocardial bridging) have not been clearly identified as independent risk factors for SCD. Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging, which appears to reflect fibrosis, is being proposed as a possible risk factor for SCD. In your opinion, when will LGE appear in guidelines as a risk factor for SCD in patients with HCM?
For my research on Coronary Artery Calcium Scoring I want to calculate the CAC mass score. Therefore I need a calibration factor for 100 kV CT scans. Does a standardized calibration factor exist for 100 kV Coronary Artery Calcium scans?
I found a log summary through google in which such calibration factors where considered. See the attached document.